Rheumatology Winter Clinical Symposium

10/30/2025

What’s next in rheumatology? RWCS 2026 explores future therapies + autoimmune breakthroughs you won't want to miss. Be one of the first to know—register now: https://buff.ly/gpU2tnF

10/27/2025

Systematic review and meta-analysis highlight HRCT as a key tool for diagnosing and characterizing ILD in CTD patients. Findings support its diagnostic value across CTDs.

A systematic review and meta-analysis examined the role of high-resolution computed tomography (HRCT) in diagnosing and characterizing interstitial lung disease (ILD) associated with connective tissue diseases (CTDs). The study analyzed 23 studies published between 2015-2024, encompassing 2020 patie...

10/25/2025

Early data from China: CAR-T therapy in 5 SLE patients showed promising results at 3 months. A potential new path for treatment-resistant lupus.

Five patients with systemic lupus erythematosus (SLE) in China have been treated with a potentially groundbreaking form of chimeric antigen receptor (CAR) T-cell therapy, researchers reported, with encouraging results after 3 months.

10/22/2025

What’s hot in rheumatology? RWCS 2026's 'Hot Topic' sessions deliver timely insights on RA, osteoporosis, and more! Stay current—don’t miss out. Register now: https://buff.ly/gpU2tnF

10/20/2025

ILD and ANCA: Global cohort studies show ANCA-positive ILD may signal underlying MPA and affect prognosis. Recognizing patterns can guide appropriate workup.

Several cohort studies conducted in Asia, Europe and the Americas have evaluated the clinical significance of antineutrophil cytoplasmic antibodies (ANCA) when detected in patients with interstitial lung disease (ILD) as well as the types of ILD encountered in patients with microscopic polyangiitis....

10/15/2025

Meta-analysis of RCTs found no increased malignancy risk in RA patients treated with biologics vs. DMARDs or placebo. Supports continued use in appropriate patients.

The risk of malignancy in rheumatoid arthritis (RA) patients receiving biologic agents was evaluated by metanalysis of randomized controlled trials (RCTs) and found no significant increased risk of malignancy compared with other disease-modifying antirheumatic drugs (DMARDs) or with placebo.

10/12/2025

Polypharmacy in early RA was linked to lower treatment response and more serious adverse events, per French study findings. Consider the impact when managing RA.

A French early rheumatoid arthritis (RA) study has shown that polypharmacy (PP) was associated with significant lower treatment responses and more serious adverse events (SAEs). Data was drawn from the French ESPOIR study, a prospective study of early RA. Polypharmacy was defined as concurrent use o...

10/10/2025

Do you have a rheumatology question or case for Dr. Cush? Record it today and you might be featured in an upcoming podcast episode!

Record a Question or Comment... Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.

10/07/2025

What is IPAF? Interstitial pneumonia with autoimmune features in patients who don’t meet CTD criteria. Recognizing it may guide monitoring and treatment decisions.

Idiopathic Interstitial Pneumonia with Autoimmune Features - or IPAF - describes patients with interstitial pneumonia with autoimmune features, but they don’t meet a diagnosis of a CTD.

10/05/2025

RA-ILD still hits hard—even as RA care advances. A Kansas City pulmonologist shares why tackling treatment complications is more urgent than ever. Watch/read now:

I'm a pulmonologist at the University of Kansas in Kansas City, and I'm excited to talk about one of my favorite topics: treatment complications in rheumatoid arthritis- associated interstitial lung disease or RA-ILD. One of the reasons I think this is a pressing and important topic is what we're de...